5 days ago1 min readOvarian Function Suppression in HR+ Premenopausal Advanced Breast Cancer ~ Wednesday, 11/20/24 Updated: 4 days agoNEW UPDATE! To register, email Trish Ferrier at trish.ferrier@tersera.com. TTL-P-1077 Speaker Program Invitation - ONS (04-2024)_T. Ferrier.pdfDownload PDF • 269KB
NEW UPDATE! To register, email Trish Ferrier at trish.ferrier@tersera.com. TTL-P-1077 Speaker Program Invitation - ONS (04-2024)_T. Ferrier.pdfDownload PDF • 269KB
The First and Only Novel Targeted Therapy Approved for mCRC, Regardless of Mutation Status, in More Than a Decade1-3
![Boston_H_color[33632]_edited.png](https://static.wixstatic.com/media/e60c5c_0b72738a80554196840094a8e387c5ed~mv2.png/v1/fill/w_338,h_77,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/Boston_H_color%5B33632%5D_edited.png)
コメント